Resumo:
(DESTINY -Breast 08)
Estudo de Fase 1b, multicêntrico, aberto, modular, de determinação da dose e expansão da dose para explorar a segurança, tolerabilidade, farmacocinética e atividade antitumoral de trastuzumabe deruxtecana(T-DXd) em combinação com outros agentes anticâncer em participantes da pesquisa com câncer de mama metastático com HER2 baixo.
Patrocinador:
AstraZeneca
Resumo:
São Paulo / SP
Instituição: IDOR São Paulo
Informações: 11 94257-9076 (WhatsApp) / 11 2109-8804
E-mail: nucleodecaptacao@idor.org
Cookie | Duração | Descrição |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |